Basil M Hantash1, Felipe Jimenez. 1. Elixir Institute of Regenerative Medicine, San Jose, CA, USA. basil@elixirinstitute.org
Abstract
BACKGROUND: Melasma is a cutaneous disorder associated with an overproduction of melanin by the tyrosinase enzyme. A proprietary oligopeptide (Lumixyl™) was previously shown to competitively inhibit mushroom and human tyrosinase in vitro without the associated cytotoxicity of hydroquinone and to diminish the appearance of facial melasma. OBJECTIVE: The aim of this case study was to determine if the Lumixyl Topical Brightening System (0.01% oligopeptide cream, an antioxidant cleanser, 20% glycolic acid lotion and physical sunscreen) accelerates clearance of mild-to-moderate melasma. RESULTS: All patients showed improvement in their facial melasma with 1 of 4 patients showing complete clearance after just 6 weeks. CONCLUSIONS: Results suggest that this regimen may be a useful new tool to treat mild to moderate melasma.
BACKGROUND: Melasma is a cutaneous disorder associated with an overproduction of melanin by the tyrosinase enzyme. A proprietary oligopeptide (Lumixyl™) was previously shown to competitively inhibit mushroom and humantyrosinase in vitro without the associated cytotoxicity of hydroquinone and to diminish the appearance of facial melasma. OBJECTIVE: The aim of this case study was to determine if the Lumixyl Topical Brightening System (0.01% oligopeptide cream, an antioxidant cleanser, 20% glycolic acid lotion and physical sunscreen) accelerates clearance of mild-to-moderate melasma. RESULTS: All patients showed improvement in their facial melasma with 1 of 4 patients showing complete clearance after just 6 weeks. CONCLUSIONS: Results suggest that this regimen may be a useful new tool to treat mild to moderate melasma.